Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1291 - Synchronous adenocarcinoma and gastrointestinal stromal tumors in the stomach


24 Nov 2018


Poster display - Cocktail


Tumour Site

Gastric Cancer;  GIST


Hilola Ubaydullaeva


H.O. Ubaydullaeva

Author affiliations

  • Endoscopy, National Cancer Research Center of Uzbekistan, 100174 - Tashkent/UZ


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1291

Case Summary

Patient. 46 years old. Female. Has been ill since 6 month. Has not another diseases. Family history free. Endoscopy has shown submucosal lesion with infiltrative tumor on the antrum. The size of the submocosal lesion was 2,5 x 3.0 cm. The overlying mucosa in the middle of the submucosal lesion was ulterated. The biopsies have taken from both sites. Histologic examination of infiltrative region revealed adenocarcinoma G3. Biopsies of submucosal lesion was negative. The physical examination and routine laboratory tests upon admission were unremarkable. The histopathologic examination after operation has revealed an adenocarcinoma G3 of stomach, that has been infiltrating into the muscular layer. In microscopic examination of submucosal lesion have been found a spindle cells neoplasm located in muscularis propria extending up to serosa. In immunohistochemical studing for desmin and CD-117 which confermed the diagnosis of gastrointestinal stromal tumor. The mitotic count was 6/50 HPF. Also, in the side with ulceration of GIST have been found cells of adenocarcinoma. The patient has been undergone distal subtotal gastrectomy and Billroth-II gastrojejunal anastomosis with D2 lymphadenectomy. The patient has not received imatinibas adjuvant therapy for the GIST, according to the international guidelines for GISTs risk stratification. The patient underwent regular clinical and radiological follow-up every 4 months after discharge. No evidence of tumor recurrence was found after 12 months of follow-up.

Editorial acknowledgement

Clinical trial identification

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.